WaferGen Completes Second Closing of Private Placement Bringing Total to $12 Million

    FREMONT, Calif., June 13 /PRNewswire-FirstCall/ -- WaferGen
 Bio-systems, Inc. a Nevada corporation (OTC Bulletin Board:   WGBS) focused
 on the development of state of the art systems for gene expression,
 genotyping and stem cell research for the life science and pharmaceutical
 industries, announced a second closing of a private placement of common
 stock and warrants to accredited investors, bringing the total proceeds
 from the private placements to $12 million.
     In addition, WaferGen named Joel Kanter and R. Dean Hautamaki, M.D. to
 the Board of Directors and Eugene A. Bauer M.D., to the position of
 Chairman of the company's Scientific Advisory Board.
     "We are delighted to bring such highly-skilled and acclaimed
 professionals to WaferGen's board: their commercial, scientific and
 financial acumen will help drive the development and commercialization of
 our novel SmartSlide(TM) and SmartChip(TM) products," said Alnoor Shivji,
 Chairman and CEO, WaferGen.
     Joel Kanter has been in the financial services industry for over three
 decades and has focused on providing equity and bridge financing to small
 and mid size companies and institutional financing to mature enterprises.
 He has served as President of Windy City, Inc., a privately held investment
 firm and as the Chief Executive Officer and President of Walnut Financial
 Services, Inc., a publicly traded company. Mr. Kanter serves on the Board
 of Directors of several public and privately held companies: Aquamatrix,
 Inc., Echo Healthcare Acquisition Corp., Modigene, Inc., I-Flow
 Corporation, Magna-Lab, Inc.,. Mr. Kanter has a B.A. in political science
 and a B.S. in psychology from Tulane University.
     R. Dean Hautamaki, M.D. is a practicing internist/pulmonary critical
 care specialist in Sarasota FL. Dr Hautamaki serves as an assistant
 clinical professor of medicine for Florida State University and is the
 principal investigator for over 40 clinical drug trials. Previously, he was
 Director of Critical Care Medicine as well as Chairman of Medicine at
 Sarasota Memorial Hospital. He graduated Alpha Omega Alpha from the
 University of Florida, College of Medicine and completed his residency and
 fellowship at Washington University School of Medicine in St Louis, MO. He
 has authored numerous articles and has lectured throughout the country on
 pulmonary disease.
     Eugene Bauer, M.D. is CEO of Neosil, Inc., a biotechnology company. Dr.
 Bauer was previously Vice President for Medical Affairs of Stanford
 University, Dean of the School of Medicine and was Chair of the Department
 of Dermatology. Dr. Bauer is one of three co-founders of Connetics Corp. He
 is a member of the boards of directors of Protalex, Inc., Echo Healthcare
 Acquisition Corp., Modigene, Inc., Peplin, Ltd. and is a member of numerous
 academic societies, including the Institute of Medicine of the National
 Academy of Sciences.
     About WaferGen
     WaferGen is focused on the development of state of the art systems for
 gene expression, genotyping and stem cell research for the life science and
 pharmaceutical industries. WaferGen's products are aimed at professionals
 who perform genetic analysis and cell biology, primarily at pharmaceutical
 and biotech companies, academic and private research centers and
 diagnostics companies involved in biomarker research. Through its SmartChip
 and SmartSlide products, WaferGen is aiding professionals in re-defining
 performance standards with significant time and cost savings in the fields
 of pharmacogenomics and toxicogenomics.
     For more information about the company, go to http://www.wafergen.com.
     Forward-Looking Statements
     This press release contains certain "forward-looking statements" within
 the meaning of the Private Securities Litigation Reform Act of 1995, as
 amended. Such statements may include statements regarding the efficacy and
 intended use of the company's technologies, the timelines for bringing such
 products to market and the availability of funding sources for continued
 development of such products and other statements that are not historical
 facts, including statements which may be preceded by the words "intends,"
 "may," "will," "plans," "expects," "anticipates," "projects," "predicts,"
 "estimates," "aims," "believes," "hopes," "potential" or similar words. For
 such statements, the company claims the protection of the Private
 Securities Litigation Reform Act of 1995.
     Forward-looking statements are not guarantees of future performance,
 are based on certain assumptions and are subject to various known and
 unknown risks and uncertainties, many of which are beyond the control of
 the company. Actual results may differ materially from the expectations
 contained in the forward-looking statements. Factors that may cause such
 differences include the risks that: (i) the company may be unsuccessful in
 commercially developing its products or in achieving market acceptance of
 new and relatively unproven technologies; (ii) the company will need to
 raise additional capital to meet its business requirements in the future
 and the company may not be able to do so on reasonable terms or at all;
 (iii) the company's proprietary intellectual property rights may not
 adequately protect its products and technologies; (iv) the company expects
 intense competition in its target markets, including from companies that
 have much greater resources than the company, and there can be no assurance
 that the company will be able to compete effectively. More detailed
 information about the company and the risk factors that may affect the
 realization of forward-looking statements is set forth in the company's
 filings with the Securities and Exchange Commission, including the
 company's Current Report on Form 8-K filed with the SEC on June 5, 2007.
 Investors and security holders are urged to read this document free of
 charge on the SEC's web site at http://www.sec.gov. The company does not
 undertake to publicly update or revise its forward-looking statements as a
 result of new information, future events or otherwise.
     Contacts:
     WaferGen
     Mona Chadha
     mona@wafergen.com
     510-651-4450
 
     For Investor Relations
     Jennifer Larson
     jlarson@labfive.com
     415-409-2729
 
 

SOURCE WaferGen Bio-systems, Inc.